Want to see JP:4599 full AI Analyst Report?
Top Page
StemRIM Inc.
(4599)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥328.00
▲(28.63% Upside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by very weak and volatile financial performance (revenue disappearing in 2024–2025, large ongoing losses, and continued cash burn), only partially offset by a low-debt balance sheet. Technicals are moderately positive with the price above major moving averages and positive MACD, but momentum is nearing overbought. Valuation remains unattractive/uncertain due to a negative P/E and no dividend yield data.
Positive Factors
Low leverage (debt effectively near zero)
Near-zero debt materially reduces solvency risk and interest burden, giving management structural flexibility to pursue R&D, partnerships or equity raises without immediate refinancing pressure. That balance-sheet optionality supports survival and strategic choices over months.
Negative Factors
Revenue collapsed to zero in 2024–2025
A complete revenue disappearance across two years is a structural red flag: it implies lost customers, ceased product sales or discontinued revenue streams. Without durable revenue restoration, the company's business model cannot cover fixed costs, threatening viability absent new durable income.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage (debt effectively near zero)
Near-zero debt materially reduces solvency risk and interest burden, giving management structural flexibility to pursue R&D, partnerships or equity raises without immediate refinancing pressure. That balance-sheet optionality supports survival and strategic choices over months.
Read all positive factors
StemRIM Inc. (4599) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥22.00B
Dividend YieldN/A
Average Volume (3M)122.86K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue GrowthN/A
EPS Growth6.10%
CountryJP
Employees45
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-29.97
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.8
Revenue Forecast (FY)¥540.00M
StemRIM Inc. Business Overview & Revenue Model
Company Description
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently under...
StemRIM Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 2.35B | 22.98M | 1.40B |
| Gross Profit | -45.01M | -49.50M | -44.35M | 2.30B | 22.98M | 1.40B |
| EBITDA | -1.90B | -1.92B | -2.03B | 190.18M | -1.93B | -550.13M |
| Net Income | -1.87B | -1.93B | -2.02B | 168.35M | -1.95B | -582.45M |
Balance Sheet | ||||||
| Total Assets | 6.36B | 7.52B | 9.09B | 10.72B | 9.61B | 10.93B |
| Cash, Cash Equivalents and Short-Term Investments | 5.71B | 6.99B | 8.41B | 10.22B | 8.88B | 10.17B |
| Total Debt | 0.00 | 0.00 | 0.00 | 531.00K | 3.67M | 6.73M |
| Total Liabilities | 232.13M | 210.27M | 194.06M | 348.51M | 207.74M | 231.10M |
| Stockholders Equity | 6.13B | 7.31B | 8.89B | 10.37B | 9.40B | 10.70B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.46B | -1.88B | 1.14B | -1.40B | -608.70M |
| Operating Cash Flow | 0.00 | -1.41B | -1.88B | 1.14B | -1.40B | -519.65M |
| Investing Cash Flow | 0.00 | -42.50M | -4.78M | -344.00K | -330.00K | -92.72M |
| Financing Cash Flow | 0.00 | 41.25M | 78.97M | 202.60M | 112.86M | 109.32M |
StemRIM Inc. Technical Analysis
Positive
255.00
Price Trends
315.60
Positive
307.27
Positive
294.81
Positive
Market Momentum
13.48
Negative
66.08
Neutral
50.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Positive. The current price of 255 is below the 20-day moving average (MA) of 331.20, below the 50-day MA of 315.60, and below the 200-day MA of 294.81, indicating a bullish trend. The MACD of 13.48 indicates Negative momentum. The RSI at 66.08 is Neutral, neither overbought nor oversold. The STOCH value of 50.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4599.
StemRIM Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ¥35.25B | -78.23 | ― | ― | 3.43% | -53.59% | |
51 Neutral | ¥22.00B | -11.71 | ― | ― | ― | 6.10% | |
47 Neutral | ¥38.07B | 58.06 | ― | ― | -47.32% | ― | |
46 Neutral | ¥7.07B | 96.35 | ― | 1.24% | -7.13% | ― | |
42 Neutral | ¥15.05B | -32.46 | ― | ― | -18.71% | -246.54% | |
42 Neutral | ¥9.23B | -7.98 | ― | ― | -56.16% | 3.12% |
* General Sector Average
JP:4599
StemRIM Inc.
351.00
46.00
15.08%
JP:4593
Healios KK
288.00
-252.00
-46.67%
JP:4880
CellSource Co., Ltd.
343.00
-258.96
-43.02%
JP:4978
ReproCELL Inc.
149.00
-32.00
-17.68%
JP:7774
Japan Tissue Engineering Co., Ltd.
848.00
354.00
71.66%
JP:7776
CellSeed Inc.
231.00
-213.00
-47.97%
StemRIM Inc. Corporate Events
StemRIM Secures South Korean Patent for Gene Therapy Targeting Rare Skin Disease
Aug 3, 2026
StemRIM Inc. said it has secured patent protection in South Korea for its stem cell gene therapy technology SR-GT1, designed as a curative treatment for dystrophic epidermolysis bullosa, a severe hereditary skin disorder caused by defects in type ...
StemRIM Wins Mexican Patent for Redasemtide Cartilage Therapy
Jul 22, 2026
StemRIM Inc. said it will soon secure a patent in Mexico for using its peptide drug Redasemtide as a therapeutic agent for cartilage disorders, including traumatic defects, osteoarthritis and osteochondritis dissecans. The patent, filed jointly wi...
StemRIM Secures Canadian Patent for Regenerative Heart Drug Redasemtide
Jul 13, 2026
StemRIM Inc. said a medical use patent for its Regeneration-Inducing Medicine candidate Redasemtide, covering cardiomyopathy, old myocardial infarction and chronic heart failure, is set to be registered in Canada, adding to existing protection in ...
StemRIM Wins South Korean Patent for Gene Therapy Targeting Rare Skin Disorder
Jul 8, 2026
StemRIM Inc. has secured patent protection in South Korea for a stem cell gene therapy technology, codenamed SR-GT1, aimed at providing a curative treatment for dystrophic epidermolysis bullosa, a severe hereditary skin disorder caused by defects ...
StemRIM to Record AMED Subsidy as Non-Operating Income for Gene Therapy Project
Jun 19, 2026
StemRIM Inc. said it will book non-operating income in the fourth quarter of the fiscal year ending July 31, 2026, after a subsidy for its regenerative medicine project was finalized. The company has secured 59.973 million yen in subsidy income fo...
StemRIM Wins Australian Patent for Redasemtide Cartilage Disorder Therapy
Jun 17, 2026
StemRIM Inc. has secured imminent patent registration in Australia for the use of its HMGB1 fragment peptide drug candidate Redasemtide as a therapeutic agent for cartilage disorders, including traumatic cartilage defects of the joint, osteoarthri...
StemRIM Wins Russian Patent to Expand Redasemtide Use in Fatty Liver and NASH
Jun 16, 2026
StemRIM Inc. has announced that a medical use patent for its regeneration-inducing drug candidate Redasemtide, covering a new therapeutic indication for fatty liver and non-alcoholic steatohepatitis, will soon be registered in Russia. The patent, ...
StemRIM posts continued loss but secures R&D runway through 2028
Jun 10, 2026
StemRIM Inc. reported a net loss of ¥1.41 billion for the nine months ended April 30, 2026, slightly improving from the previous year’s loss, with no operating revenue booked and basic earnings per share at a loss of ¥22.51. Total ...
StemRIM Plans Tax-Efficient Capital Reduction Ahead of July Extraordinary Meeting
May 13, 2026
StemRIM Inc. has set June 1, 2026 as the record date for shareholders eligible to vote at an extraordinary general meeting scheduled for July 29, 2026 in Osaka. The sole agenda item will be a proposed reduction of the company’s stated capita...
StemRIM Highlights Shionogi’s Timelines for Regenerative Drug Redasemtide in DEB and Stroke
May 12, 2026
StemRIM said partner Shionogi has set out an updated clinical and commercialization timeline for Redasemtide, a peptide drug derived from HMGB1 and licensed from StemRIM as a flagship “Regeneration-Inducing Medicine”. Shionogi is runni...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.